Biomarkers and Parkinson's disease
Identifieur interne : 001668 ( Main/Exploration ); précédent : 001667; suivant : 001669Biomarkers and Parkinson's disease
Auteurs : A. W. Michell [Royaume-Uni] ; S. J. G. Lewis [Royaume-Uni] ; T. Foltynie [Royaume-Uni] ; R. A. Barker [Royaume-Uni]Source :
- Brain [ 0006-8950 ] ; 2004-08.
English descriptors
- KwdEn :
Abstract
Biomarkers are characteristics that can be measured as an indicator of a normal biological process, and they have special relevance in Parkinson's disease. Parkinson's disease is a chronic neurodegenerative disorder that is difficult to study, given the site of pathology and because the resultant clinical phenotype fluctuates over time. We currently have no definitive diagnostic test, and thus for the clinician there is hope that biomarkers will help diagnose symptomatic and presymptomatic disease or provide surrogate end-points to demonstrate clinical efficacy of new treatments, such as neuroprotective therapies, and help stratify this heterogeneous disease. No biomarker is likely to fulfil all these functions, so we need to know how each has been validated in order to understand their uses and limitations, and be aware of potential pitfalls. In this review we discuss the current potential biomarkers for Parkinson's disease, highlight the problems with their use, and conclude with a discussion of future alternatives.
Url:
DOI: 10.1093/brain/awh198
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biomarkers and Parkinson's disease</title><author><name sortKey="Michell, A W" sort="Michell, A W" uniqKey="Michell A" first="A. W." last="Michell">A. W. Michell</name></author><author><name sortKey="Lewis, S J G" sort="Lewis, S J G" uniqKey="Lewis S" first="S. J. G." last="Lewis">S. J. G. Lewis</name></author><author><name sortKey="Foltynie, T" sort="Foltynie, T" uniqKey="Foltynie T" first="T." last="Foltynie">T. Foltynie</name></author><author><name sortKey="Barker, R A" sort="Barker, R A" uniqKey="Barker R" first="R. A." last="Barker">R. A. Barker</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9226EEB0919EF5775D2F0C6217E2D466F781DA52</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1093/brain/awh198</idno><idno type="url">https://api.istex.fr/document/9226EEB0919EF5775D2F0C6217E2D466F781DA52/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000D18</idno><idno type="wicri:Area/Main/Curation">000B62</idno><idno type="wicri:Area/Main/Exploration">001668</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Biomarkers and Parkinson's disease</title><author><name sortKey="Michell, A W" sort="Michell, A W" uniqKey="Michell A" first="A. W." last="Michell">A. W. Michell</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cambridge Centre for Brain Repair, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Lewis, S J G" sort="Lewis, S J G" uniqKey="Lewis S" first="S. J. G." last="Lewis">S. J. G. Lewis</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cambridge Centre for Brain Repair, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Foltynie, T" sort="Foltynie, T" uniqKey="Foltynie T" first="T." last="Foltynie">T. Foltynie</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cambridge Centre for Brain Repair, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Barker, R A" sort="Barker, R A" uniqKey="Barker R" first="R. A." last="Barker">R. A. Barker</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cambridge Centre for Brain Repair, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain</title><title level="j" type="abbrev">Brain</title><idno type="ISSN">0006-8950</idno><idno type="eISSN">1460-2156</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2004-08">2004-08</date><biblScope unit="volume">127</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1693">1693</biblScope><biblScope unit="page" to="1705">1705</biblScope></imprint><idno type="ISSN">0006-8950</idno></series><idno type="istex">9226EEB0919EF5775D2F0C6217E2D466F781DA52</idno><idno type="DOI">10.1093/brain/awh198</idno><idno type="local">awh198</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8950</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DAT = dopamine transport</term><term>MIBG = metaiodobenzylguanidine</term><term>MSA = multiple system atrophy</term><term>Parkinson's disease</term><term>SPECT = single-photon emission computed tomography</term><term>biomarkers</term><term>diagnosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Biomarkers are characteristics that can be measured as an indicator of a normal biological process, and they have special relevance in Parkinson's disease. Parkinson's disease is a chronic neurodegenerative disorder that is difficult to study, given the site of pathology and because the resultant clinical phenotype fluctuates over time. We currently have no definitive diagnostic test, and thus for the clinician there is hope that biomarkers will help diagnose symptomatic and presymptomatic disease or provide surrogate end-points to demonstrate clinical efficacy of new treatments, such as neuroprotective therapies, and help stratify this heterogeneous disease. No biomarker is likely to fulfil all these functions, so we need to know how each has been validated in order to understand their uses and limitations, and be aware of potential pitfalls. In this review we discuss the current potential biomarkers for Parkinson's disease, highlight the problems with their use, and conclude with a discussion of future alternatives.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Michell, A W" sort="Michell, A W" uniqKey="Michell A" first="A. W." last="Michell">A. W. Michell</name></noRegion><name sortKey="Barker, R A" sort="Barker, R A" uniqKey="Barker R" first="R. A." last="Barker">R. A. Barker</name><name sortKey="Foltynie, T" sort="Foltynie, T" uniqKey="Foltynie T" first="T." last="Foltynie">T. Foltynie</name><name sortKey="Lewis, S J G" sort="Lewis, S J G" uniqKey="Lewis S" first="S. J. G." last="Lewis">S. J. G. Lewis</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001668 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001668 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9226EEB0919EF5775D2F0C6217E2D466F781DA52
|texte= Biomarkers and Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |